Prussian Blue Nanozyme Disrupts the Self‐Reinforcing Loop of Tauopathy via Triple‐Action Mechanism
Advanced Healthcare Materials · 2026
DOI: 10.1002/adhm.202505286 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2026. Verfasst von Fei Wu und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine, Chinese Academy of Sciences, Hangzhou, China. Hauptthemen laut MEDLINE: Ferrocyanides, Tauopathies. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Fundamental Research Funds for the Central Universities.
Abstract (Originalsprache)
Tauopathies, such as Alzheimer's disease, are driven by a self‐reinforcing pathological triad of tau aggregation, oxidative stress, and autophagy dysfunction, which remains inadequately addressed by single‐target therapies. Herein, we engineer an ultrasmall Prussian blue nanozyme (PBzyme) as a multienzyme‐mimetic and multi‐target agent to concurrently disrupt this vicious cycle. PBzyme functions as a potent tau fibril inhibitor, with molecular dynamics simulations revealing high‐affinity binding to β‐sheet domains (−400 kJ/mol), thereby reducing tau phosphorylation and hippocampal burden. In parallel, PBzyme acts as a multifunctional antioxidant enzyme mimic, efficiently neutralizing •OH, O 2 − , and H 2 O 2 to alleviate oxidative injury. Furthermore, PBzyme restores autophagic flux by activating AMPK/ULK1 signaling while inhibiting the mechanistic target of rapamycin (mTOR), thereby promoting the clearance of tau aggregates. In an okadaic acid–induced tauopathy rat model, PBzyme treatment effectively preserved synaptic integrity, suppressed neuroinflammation, mitigated neuronal loss, and rescued cognitive deficits. Notably, PBzyme enters cells to counteract intracellular tau and ROS, overcoming a key limitation of conventional biologics. This work establishes PBzyme as an integrated nanoagent offering a synergistic therapeutic strategy against tauopathies and other ROS‐related neurodegenerative diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine, Chinese Academy of Sciences, Hangzhou, China.
- Department of Nuclear Medicine and PET Center, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
- Institute of Nuclear Medicine and Molecular Imaging of Zhejiang University, Hangzhou, China.
- Key Laboratory of Medical Molecular Imaging of Zhejiang Province, Hangzhou, China.
- Shanghai Key Laboratory of Neuro-Ultrasound for Diagnosis and Treatment, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Key Laboratory for Biomedical Engineering of Ministry of Education, Zhejiang University, Hangzhou, China.
ORCID-Profile: Fei Wu, Hong Zhang
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Fundamental Research Funds for the Central Universities
- Zhejiang Provincial Natural Science Foundation of China
- Innovative research team of high-level local universities
Zitieren
APA
Wu, F., Huang, J., Wang, J., Wu, R., Zhang, H., Jin, C., Chen, C., Zhou, R., Cen, P., Tian, L., Zheng, Y., Cai, X., Tian, M., Zhang, H., & Zhong, Y. (2026). Prussian Blue Nanozyme Disrupts the Self‐Reinforcing Loop of Tauopathy via Triple‐Action Mechanism. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202505286
Vancouver
Wu F, Huang J, Wang J, Wu R, Zhang H, Jin C, et al. Prussian Blue Nanozyme Disrupts the Self‐Reinforcing Loop of Tauopathy via Triple‐Action Mechanism. Advanced Healthcare Materials. 2026. doi:10.1002/adhm.202505286
BibTeX
@article{Wu2026,
author = {Wu, Fei and Huang, Jiani and Wang, Jing and Wu, Rongrong and Zhang, Hang and Jin, Chentao and Chen, Cheng and Zhou, Rui and Cen, Peili and Tian, Liangfei and Zheng, Yuanyi and Cai, Xiaojun and Tian, Mei and Zhang, Hong and Zhong, Yan},
title = {Prussian Blue Nanozyme Disrupts the Self‐Reinforcing Loop of Tauopathy via Triple‐Action Mechanism},
journal = {Advanced Healthcare Materials},
year = {2026},
doi = {10.1002/adhm.202505286}
}
EUVIMED